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Abstract
The recent studies have evaluated the relationship between BRCA1 expression and clinical outcome of
chemotherapy (mainly focused on platinum-based and toxal-based treatment) in NSCLC patients, but the results
were inconclusive and controversial. Our aim of this study was to evaluate this association by literature based
system review and meta-analysis.
PubMed, EMBASE and the China National Knowledge Infrastructure (CNKI) databases were used to retrieve the
relevant articles. The interested outcome included objective response rate (ORR), overall survival (OS) and event-free
survival (EFS). The pooled odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) ware estimated.
After specific inclusion and exclusion criteria, 23 studies fulfilled the criteria and were included in our analysis. In 17
platinum-based studies, low/negative BRCA1 was in favor of better ORR (OR = 1.70, 95%CI = 1.32-2.18), longer OS
and EFS (HR = 1.58, 95%CI = 1.27-1.97, and HR = 1.60, 95%CI = 1.07-2.39 for OS and EFS, respectively). In 4 toxal-based
chemotherapy studies, the patients with high/positive BRCA1 had better ORR (OR = 0.41, 95%CI = 0.26-0.64), OS and
EFS were not evaluated as the insufficient data available.
Overall, BRCA1 might be a useful biomarker to predict clinical outcome for personal chemotherapy in NSCLC patients
in the future.
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Introduction
Lung cancer is now the most commonly diagnosed cancer
and the leading cause of cancer death worldwide [1]. In
USA, 412,230 cases had lung cancer history and the new
cases estimated in 2012 were 226,160. Most of lung cancers
(56%) are diagnosed at an advanced stage as the typically
asymptomatic in early stage. Lung cancer is classified into
primarily two subgroups: small-cell lung cancer (SCLC)
and non-small-cell lung cancer (NSCLC), and the later
accounts for approximately 85% of all lung cancers.
Although the notable progress has been made in lung
therapy, this disease is still associated with a poor prognosis
and has few effective treatment options. The overall 5-year
survival rate for NSCLC is 17.1% [2].
The chemotherapy efficacy is varied from different indi-
vidual, even in patients with similar clinical and pathologic
features, the outcome varies: some complete released, some
are stable or even progression. So some authors consider
NSCLC as a heterogeneous disease [3]. The genetic factor
may contribute greater to this diverse efficacy, the SNPs or
gene expression products (mRNA and protein) could be
special biomarkers. As the development of biochemistry,
some notable biomarkers such as EGFR, VEGF, were identi-
fied to predict lung cancer treatment outcome, breast
* Correspondence: Xianlei59@163.com
†Equal contributors
1Department of Cardiothoracic Surgery, the First Affiliated Hospital of
Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region
530021, China
Full list of author information is available at the end of the article
© 2013 Yang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Yang et al. Journal of Experimental & Clinical Cancer Research 2013, 32:15
http://www.jeccr.com/content/32/1/15
cancer susceptibility gene 1 (BRCA1) has emerged as one
of the most appealing genetic markers among them.
BRCA1 located in chromosome 17q21, and was identified
as a breast and ovarian cancer susceptibility gene. BRCA1
germline mutations have been correlated to the increasing
risk of developing breast and ovarian cancer [4,5]. Recent
studies have shown that the protein encoded by this gene is
a nuclear phosphoprotein and has multiple roles not only
in DNA damage repair but also in cell cycle checkpoint or
cell death machinery [6,7]. A greater sensitivity to cisplatin
with decreased BRCA1 mRNA expression and a greater
resistance to the paclitaxel with increased BRCA1 mRNA
expression was observed in breast cancer cell lines [7,8].
Also in tumour cells isolated from malignant effusions of
NSCLC and gastric cancer patients, the same effect was
observed [9].
Followed by in vitro studies, clinical studies explored this
relationship. Taron et al. [10] firstly examined the potential
role of BRCA1 mRNA expression in predicting differential
chemotherapy sensitivity in NSCLC, and found the patients
with high BRCA1 had poor outcome while those with low
had better outcome. Followed by Taron, a series of studies
evaluated the relationship between BRCA1 level and
chemotherapy outcome. The chemotherapy regimens were
mainly focused on platinum-based and toxal-based treat-
ment. However, the results were inconclusive due to the
limited sample size and the limited statistics power.
Current study provided a comprehensive assessment
on the association between BRCA1 level and the




Relevant studies were searched in PubMed, EMBASE and
China National Knowledge Infrastructure (CNKI) databases
using the following terms: “BRCA1 or Breast cancer
susceptibility gene 1 or Breast cancer 1” and “NSCLC
or non-small-cell lung cancer”. The last research time
was December 10, 2012.
Inclusion criteria
The following criteria were used to select publications:
(1) studies published in English and Chinese regardless
of publication time; (2) reviews, animal or cell line studies
should be excluded; (3) the NSCLC patients should be
pathologically confirmed; (4) BRCA1 expression should be
detected by immunohistochemistry (IHC) or reverse-
transcriptase polymerase chain reaction (RT-PCR); (5) the
studies should provided the clinical outcomes such as
objective response rate (ORR) to chemotherapy, overall sur-
vival (OS) or event-free survival (EFS) with HR and 95%CI,
EFS was classified as progression-free survival (PFS),
disease-free survival (DFS) and time to progression (TTP).
Data collection
Publication characteristics details such as first author’s
name, publication year, patients’ original country, sample
type, detection method of BRCA1, sample size, middle/
mean age of study sample, disease stage were collected
for each eligible publication. End points of interest were
objective response rate (ORR), overall survival (OS), and
event-free survival (EFS).
Statistical analysis
To estimated ORR, the patients were divided into
responders and non-responders. The responders were
defined as complete response (CR) and partial response
(PR) and the non-responders including stable disease (SD)
and progressive disease (PD). The pooled odds ratio (OR)
and its 95% confidence intervals (CIs) were calculated by
the methods proposed by Mantel and Haenszel [11], or by
DerSimonian R and Laird N [12]. For time-to-event data-
OS and EFS, the hazard ratios (HRs) and associated 95%
confidence interval (CI) were estimated using the methods
reported by Parmar [13].
The between study heterogeneity was determined by
Q test and I2 metric (I2 = 0–25%: no heterogeneity;
I2 = 25–50%: moderate heterogeneity; I2 = 50–75%:
large heterogeneity; I2 = 75–100%: extreme heterogeneity)
[14]. The fixed-effect model was applied in the initial ana-
lysis, and if the significant heterogeneity existed, then the
confirmed random-effect model was used. Begg’s test was
used to evaluate the publication bias. P < 0.05 indicated
significant publication bias [15]. All P value was two-tailed,
and STATA version 11.1 (Stata Corporation, USA) was
used to perform the most of data analysis.
Results
Eligible studies
188 potentially relevant studies were identified through
the search strategy. After checking the title and abstract,
134 studies excluded because it was very clear that
their design didn’t meet our inclusion criteria. Then
the full texts of 54 articles were carefully screened, 29
studies were excluded as data insufficiency that we
could not extract the data for analysis, 2 studies were
excluded for potential data overlap as the same insti-
tute conducted the research and their patients
recruitment time may exist overlap. Finally, a total of
23 studies were eligible for the final analysis. Among
them, 19 studies estimated the relationship between
BRCA1 and platinum-based chemotherapy outcome
[10,16-33], 3 were toxal-based [34-37]. Additional one
studies evaluated the toxal-based in fist-line chemothe-
rapy and a part of patients received platinum-based
treatment [36]. The study selection process was showed
in Figure 1.
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Study characteristics
Our meta-analysis composed 23 studies [10,16-37] inclu-
ding 2606 NSCLC patients. The sample size variant from
34 to 769, 17 studies were about East-Asian population
[16-25,27,28,30,32-34,37], 5 studies were about Caucasian
[10,26,29,35,36] and 1 studies may contain different races
as the samples were from the prospective randomized
clinical trial International Adjuvant Lung Trial (IALT)
[31]. In this multi-center study, the author’s intention was
to investigate the predictive and prognostic role of BRCA1
level in squamous cell carcinoma (SCC) and adenocarci-
noma (ADC), so both OS and EFS were conducted in 2
groups (SCC and ADC). Table 1 summarized the main
characteristics of included studies.
BRCA1 level and the clinical outcome of chemotherapy
The relationship between BRCA1 level and the clinical
outcome was presented in Table 2 and Figures 2, 3, 4, 5.
1. Platinum-based chemotherapy
16 studies [10,16-29,33] composed 1330 patients
reported the data on ORR. Low/negative BRCA1
expression was observed in 591 patients (account for
44.4%) and the high/positive expression was in 739
patients (55.6%). It seemed that patients bearing
low/negative BRCA1 had a higher ORR to platinum-
based chemotherapy than those bearing high/positive
BRCA1 level (48.9% vs 38.1%, OR = 1.70, 95%CI =
1.32-2.18, I2 = 44.7%, P = 0.03 for heterogeneity)
(Figure 2). No publication bias was observed (P = 0.15).
In subgroup analysis based on BRCA1 detection
method, there were 13 IHC studies (1066 patients)
[16,17,19,21-28,33] and 4 RT-PCR studies (264
patients) [10,18,20,29], the distribution of low/
negative BRCA1 was similarity(IHC vs RT-PCR:
44.5% vs 44.3%). Both of them found the significant
association (for IHC studies, 50.7% vs 39.0%,
OR = 1.54, 95%CI = 1.17-2.00, I2 = 44.8%, P = 0.03
for heterogeneity; for RT-PCR studies, 43.7% vs
25.0%, OR = 2.91, 95%CI = 1.55-3.83, I2 = 0.0%,
P = 0.52 for heterogeneity), When we stratified
studies according to their origin, 13 studies were
conducted in East-Asian [16-25,27,28,33] and only
3 were Caucasian [10,26,29]. The low/negative
BRCA1 level distribution in Caucasian was lower
than East-Asian (38.6% vs 45.4%).The significant
association was found in East-Asian population
rather than Caucasian: for East-Asian, 51.0% vs
36.0%, OR = 1.68, 95%CI = 1.30-2.19, I2 = 39.9%,
P = 0.04 for heterogeneity; for Caucasian, 39.8%
Figure 1 The flow chart of study selection and exclusion.
Yang et al. Journal of Experimental & Clinical Cancer Research 2013, 32:15 Page 3 of 9
http://www.jeccr.com/content/32/1/15
vs 33.4%, OR = 1.77, 95%CI = 0.50-6.28, I2 = 63.6%,
P = 0.06 for heterogeneity. However, the relationship
between BRCA1 level and ORR in Caucasian
population could not be determined as the sample
size was not large enough.
7 studies consisted of 3 East-Asian [18,30,32] and
4 Caucasian [10,26,29,31] including 733 patients
were used to analyzed the OS. The significant
association between BRCA1 expression and OS in
platinum-based treatment was detected. Patients
bearing low/negative BRCA1 was more likely to have
longer survival time. (HR = 1.58, 95%CI = 1.27-1.97,
I2 = 48.4%, P = 0.03 for heterogeneity) (Figure 3),
no publication bias was observed (P = 0.13).
EFS data were available for 5 studies [26,29,31,32,36]
with 599 patients (3 were PFS [26,29,32], one was
DFS [31] and the other one was TTP [36]),only one
study was about East-Asian[32]. It seemed that
patients with low/negative BRCA1 had longer EFS
than those with high level, even there was no
publication bias, but heterogeneity existed between
studies. (HR = 1.60, 95%CI = 1.07-2.39) (I2 = 54.5%,
P = 0.02 for heterogeneity) (Figure 4).
2. Taxol-based chemotherapy
Since only 2 studies [35,36] presented the sufficient
data of OS and EFS that ensured us to conducted
meta-analysis. We didn’t evaluate the relationship
between BRCA1 expression and OS/EFS. In ORR
analysis, we applied 4 eligible studies (2 East-Asian and
2 Caucasian) [34-37] in our meta-analysis. A total of
375 patients were included in this comparison. Among
375 patients, 155 patients (account for 41.3% of total)
bared low/negative BRCA1 and the remaining 220
patients (account for 58.7% of total) bared high/
positive BRCA1. An interesting conclusion was found:
opposite to platinum-based treatment, NSCLC
patients bearing high/positive BRCA1 were more likely
to respond to toxal-based treatment when compared
with those bearing the low/negative (low/negative
vs high/positive: 26.0% vs 46.1%, OR = 0.41,
95%CI = 0.27-0.64, I2 = 0.0%, P = 0.61 for heterogeneity)
(Figure 5). No publication bias existed (P = 0.84).
Table 1 Characteristics of eligible studies evaluating BRCA1 level and clinical outcome












Taron,2004 [10] Spanish 60 NR RT-PCR llb,lll GP ORR,OS
Ota,2009 [16] Japan 156 62 IHC IV NP,DC,PI,GP,paclitaxel/carboplatin ORR,
Shang,2009 [17] China 60 54 IHC llllll platinum-based ORR
Yang,2009 [18] China 75 57 RT-PCR lllB, IV NP,TP ORR,OS
Shan,2009 [19] China 81 62 IHC lllB, IV NP,GP,TP ORR
Wang,2010 [20] China 34 61 RT-PCR lllB, IV GP ORR
Lu,2010 [21] China 65 62.4 IHC lllB, IV GP ORR
Mo,2011 [22] China 80 50 IHC lll, IV GP,NP,TP ORR
Gao,2011 [23] China 122 60 IHC lllB, IV platinum-based ORR
Wan,2011 [24] China 87 58 IHC lllB, IV TP ORR
Zhang,2011 [25] China 136 61 IHC lll, IV GP,NP,TP ORR
Chen,2011 [33] China 152 NR IHC lllB, IV GP,NP,TP ORR
Joerger,2011 [26] Netherlands 42 59.3 IHC lllB, IV GP ORR,OS,PFS
Fujii,2011 [27] Japan 35 58 IHC lll neoadjuvant chemotherapy and chemoradiotherapy(PI,DC) ORR,OS
Gu,2012 [28] China 50 NR IHC llllll neoadjuvant chemotherapy(NP,GP) ORR
Papadaki,2012 [29] Greece 100 63 RT-PCR IV 2nd line PI,Cisplatin,Cisplatin + pemetrexed ORR,OS,PFS
Zeng,2010 [30] China 63 64 IHC llllll NP,GP,EP OS
Pierceall,2011 [31] Multi-center 769 NR IHC llllll platinum-based,no treatment OS,DFS
Leng,2012 [32] China 85 57 RT-PCR llllll,IV GP,NP,TP OS,DFS
Boukovinas,2008 [36] Greece 96 60 RT-PCR lllB, IV 1st line DG,2nd line platinum-based ORR,OS,TTP
Su,2011 [34] China 63 60 RT-PCR lllB, IV toxal-based OS,
Papadaki,2011 [35] Greece 131 60 RT-PCR lllB, IV DG,DC ORR,OS,PFS
Zhou,2012 [37] China 64 58 IHC lll, IV toxal-based ORR
Note: RT-PCR: real-time reverse transcriptase polymerase chain reaction, IHC: immunohistochemistry, GP: gemcitabine/platinum, NP: vinblastine/platinum,
DC: docetaxel/cisplatin, PI: platinum/irinotecan, TP: toxal/platinum, NR not reported, PFS: progression-free survival, DFS: disease-free survival, TTP: time to progression.
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Discussion
Although the relationship between BRCA1 expression and
chemotherapy outcomes of NSCLC has been investigated
by previous studies, the results were inconsistent and some
were even conflicting. So a systematic review and meta-
analysis based on the published literature was necessary to
give further insights on this conflicting issue. Our meta-
analysis showed that for platinum-based chemotherapy,
low/negative BRCA1 expression were associated with not
only better ORR, but also longer OS and EFS, but for toxal-
based chemotherapy, high/positive BRCA1 was associated
with better ORR.
Platinum agents can bind to DNA and form complexes
thus inducing intra- and inter-strand DNA, as well as
DNA-protein cross-links and results in cell growth inhi-
bition and apoptosis. As one of ant-tubulin agents, taxol in-
hibits cell division by enhancing formation and stabilization
of microtubules and disrupts the mitotic spindle assembly,
Table 2 The summary meta-analysis results of association between BRCA1 level with objective response rate (ORR),
overall survival (OS) and event-free survival (EFS) in platinum- and toxal-based treatment













ORR overall 16(1330) 44.4 48.9 vs 38.1 1.70 (1.32, 2.18), 1.80(1.26,2.55) I2 = 44.7%,P = 0.03 0.15
Method
IHC 13(1066) 44.5 50.7 vs 39.0 1.54(1.17,2.00), 1.59(1.07,2.36) I2 = 44.8%,P = 0.03 0.41
RT-PCR 4(264) 44.3 43.7 vs 25 2.91 (1.55, 3.83), 2.91(1.55,5.47) I2 = 0.0%, P = 0.52 0.76
Origin
East-Asian 14(1133) 45.4 51.0 vs 36.0 1.68(1.30,2.19), 1.79(1.24,2.60) I2 = 39.9%,P = 0.04 0.10
Caucasian 3(197) 38.6 39.8 vs 33.4 1.79 (0.84, 3.83), 1.77(0.50,6.28) I2 = 63.6%,P = 0.06 0.90
OS 8(733) - - 1.58(1.27,1.97), 1.65(1.19,2.89) I2 = 48.4%,P = 0.03 0.13
EFS 6(599) - - 1.62(1.28,2.05), 1.60(1.07,2.39) I2 = 54.5%,P = 0.02 0.88
Toxal-based
ORR overall 4(376) 41.3 26.0 vs 46.1 0.41(0.26,0.64), 0.41(0.27,0.64) I2 = 0.0%, P = 0.61 0.84
Figure 2 Forest plot for the association between BRCA1 level and objective response rate (ORR) in platinum-based treatment.
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and a surveillance mechanism known as the spindle check-
point at the metaphase-anaphase transition have been acti-
vated. It leads to the abrogation of the spindle checkpoint,
results in unequal segregation of chromosomes and aneu-
ploidy [38].
Like excision repair cross complementing 1 (ERCC1),
xeroderma pigmentosum group D and G (XPD, XPG),
BRCA1 belongs to nucleotide excision repair (NER) system
[39], which has been reported to be the mayor repair sys-
tem that reduced platinum-induced DNA damage. BRCA1
involves in homologous recombination, nonhomologous
end joining, mismatch repair and other effects though
its interaction with other DNA repair gene such as
ATM, ATR, RAD51, RAD50, MRE11, NBS1. BRCA2
and so on [7]. The reason that high/positive BRCA1
could predict the good response to taxol is still not
clear, 3 mechanisms had been proposed in explained
this issue: (1) trigger cell cycle arrest in G2/M phase,
(2) enhance apoptosis through a pathway involving
H-Ras, MEKK4, JNK, and activation of caspases 8
and 9, (3) participate in spindle assembly checkpoint
signaling [6,40].
Figure 3 Forest plot for the association between BRCA1 level and overall survival (OS) in platinum-based treatment.
Figure 4 Forest plot for the association between BRCA1 level and event-free survival (EFS) in platinum-based treatment.
Yang et al. Journal of Experimental & Clinical Cancer Research 2013, 32:15 Page 6 of 9
http://www.jeccr.com/content/32/1/15
BRCA1 gene showed an interesting outcome in NSCLC
chemotherapy. Several cell studies and our meta-analysis
based on clinical trials demonstrated low/negative BRCA1
expression could benefit from platinum-based chemother-
apy; in contrast, the high level of BRCA1 expression was in
favor of toxal contained agents. This may confuse us, how
could we determine chemotherapy choice properly? Rosell
customized treated 84 patients based on their BRCA1
expression: low, cisplatin plus gemcitabine (GP); intermedi-
ate, cisplatin plus docetaxel (DC); high, docetaxel alone.
The median survival (MS) and 2-year survival of low
BRCA1 patients received GP regime was 11 month and
41.2%, which seem to be favorable with the traditional
randomized trial treated with GP or pemetrexed plus
cisplatin. The MS of high BRCA1 patients received single-
agent docetaxel was 11 month and had no detrimental
effect when compared with a large phase III trial in patients
treated with DC [41]. If this hypothesis is validated, the
NSCLC patients with high BRCA1 should receive taxol
based and non-platinum-contained adjuvant chemotherapy,
which would be more economic, efficacy and less
toxic effect for patients. However, more multi-center
prospective clinical trials should be conducted to confirm
this hypothesis.
Since BRCA1 mRNA and protein level was associated
with treatment efficacy, why other biomarkers such as
SNPs in this gene could be a choice? But in another hand,
it seems that gene expression level provides direct evidence
and SNPs provide indirect evidence as it is usually gene
product especially protein rather than gene itself play an
import role in biochemical activity. Although SNPs are
important gene variant that affect the protein expression,
but many factors involve in protein synthesis. We found
that studies evaluated the SNPs in BRCA1 gene and the
clinical outcome was limited. Su [42] found that BRCA1
S1613G was associated with platinum-based chemotherapy
efficacy in objective response rate. In a large trail consisted
of 300 NSCLC patients at stages III and IV, AACC haplo-
type but not single S1613G in BRCA1 was associated with
poor overall survival (hazard ratio = 2.097; 95%CI, 1.339 to
3.284) treated with platinum combination chemotherapy
[43]. However, whether SNPs or haplotypes were associated
with clinical outcome was still under debate since lacking
of enough evidence.
To interpret the results of meta-analysis, several impor-
tant acknowledgments should be addressed. First, did the
BRCA1 assessment methodology consistently? As we know,
IHC detects gene expression at protein level, while RT-PCR
assays at mRNA level. From mRNA to protein, many
factors such as transcription, post-transcriptional regula-
tion, translation and post-translation may affect this
process. Besides, RT-PCR uses the bulk tumor/tissue to
extract RNA, while IHC can distinguish cell type and can
read protein level only in cancer cell when compared with
normal epithelial cell. Even in studies using IHC or RT-
RCR assessment methodology, their cutoff value was incon-
sistently. Although in subgroup analysis based on BRCA1
detecting methods in platinum-based treatment, both IHC
and RT-PCR showed the significant association between
BRCA1 level and ORR, the potential heterogeneity may
exist. Also, what’s the proper cutoff that could predict the
chemotherapy efficacy to a great extent? We are looking
forward the future researches explore this relationship.
Second, is the platinum-based chemotherapy the pure plat-
inum and the toxal-based chemotherapy the pure toxal?
BRCA1 gene shows the different mechanism and efficacy in
platinum and toxal regimens. As cell experiments suggest
that low/negative BRCA1 benefit from platinum whereas
high/negative BRCA1 benefit more from anti-tubulin regi-
men such as paclitaxel and docetaxel. But in practice, single
Figure 5 Forest plot for the association between BRCA1 level and objective response rate (ORR) in toxal-based treatment.
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agent in chemotherapy is impossible as the limited efficacy.
Platinum is usually combined with anti-tubulin agents, for
example, toxal and platinum (TP), docetaxel and carbo-
platin (DC). In our meta-analysis, we sorted the studies into
platinum-based studies means that every patient received
platinum agents (cisplatin, carboplatin or oxaliplatin), the
toxal-based chemotherapy means that every patient
received toxal contained agents (toxal, taxane or docetaxel).
Although our meta-analysis showed that patients with
low/negative BRCA1 have better objective response
rate and longer OS and EFS, and patients with high/positive
BRCA1 have better ORR, the confounding factors from
chemotherapy agents may exist in studies. Third, is BRCA1
an important predict or prognosis factor to the clinical
outcome? Many factors may contribute to the ORR, OS as
well as EFS, for example, age, smoking status, pathological
type, tumor stage, the drug dosage and treatment cycle, also
the genetic as well as gene-environment interaction also
involve in disease progression, there were not enough base-
line characters that ensure us to conduct stratified analysis.
Four, were all relevant studies included in the analysis? This
is impossible and difficult to assess. Although we searched
and collected relevant studies until the December 10, 2012
to our best effort, there were still some studies with nega-
tive results did not presented the sufficient data and some
were failed to get published. In our meta-analysis, only 3
Caucasian studies including 197 patients evaluated the
ORR in platinum-based treatment. In toxal-based chemo-
therapy studies, only 4 studies consisted of 376 patients
evaluated this association. The small sample size may
mislead us and draw a wrong conclusion. Besides,
except for one multi-center study [31], our included
samples were mainly distributed in some countries in
East-Asian (Chinese and Japanese) and European
(Spanish, Greece). So few studies could we found in other
countries such us USA, Canada, UK, German, France and
so on. Also, the African population was limited. This
disequilibrium of population distribution may also affect
our results.
Conclusions
Despite the limitations of this meta-analysis, our study
confirmed that low/negative BRCA1 expression was
associated with better objective response rate (ORR)
and longer overall survival (OS) and event-free sur-
vival (EFS) in NSCLC patients treated with platinum-
containing regimen, while high/positive BRCA1 level
were associated with better objective response rate in
toxal contained regimen. Therefore, BRCA1 might
serve as a valuable marker for personal chemotherapy.
However, considering the limitation our meta-analysis,
multi-center of larger studies with hundreds or thou-
sands of subjects and strict designed methodology
was expected.
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